New Board of Directors

We’re excited to announce three new members to our Board of Directors!

Franziska Stemmler brings over 25 years of experience in the MedTech and pharmaceutical sectors, having held diverse roles across operations, marketing, and business development. She is a certified systemic coach with substantial expertise within the startup ecosystem. Throughout her career, Franziska has led organizational development initiatives, managed operations and resources to enhance process efficiencies, and advanced growth strategies. Her focus has consistently been on fostering team development, optimizing operational performance, and promoting cross-functional collaboration. Her experience includes evaluating potential investments in innovative life sciences startups and managing related portfolios. She developed and advanced brand presence through the execution of comprehensive brand strategies. Additionally, Franziska collaborated closely with research teams and coordinated investor relations and partnership negotiations.

Prof. Dr. med. Simone Schrading is Professor of Medical Sciences and Chief Radiologist at the Lucerne Cantonal Hospital (LUKS), where she heads the research division. She studied medicine at the University of Bonn, completing her doctorate in 2004 and her radiology training in 2010. From 2010 to 2019, she held senior positions at RWTH Aachen University Hospital, leading breast imaging, MRI, and pediatric radiology. In 2015, she received the Venia Legendi from RWTH Aachen. Since 2019, Simone has focused on advancing imaging in oncology, with particular emphasis on MRI and artificial intelligence. Her research aims to improve tumor diagnostics and integrate innovative technologies into clinical radiology.

Hendrik Tevaearai Stahel studied medicine in Lausanne, where he trained as cardiovascular surgeon (FMH). He is a professor at the University of Bern, where he developed and led a large group of fundamental, technical, and clinical researchers. In 2008, he founded Swiss Cardio Technologies, a pharmaceutical start-up specializing in an innovative heart medication that recently received market authorization. Hendrik is now independent consultant for medical and medtech companies seeking specific expertise in all aspects of translational development, including R&D, IP, strategic and structural development, and regulatory affairs.

Welcome Franziska Stemmler, Prof. Dr. med. Simone Schrading and Hendrik Tevaearai Stahel!